HK Stock Market Move | HUA MEDICINE-B(02552) rose over 12%, achieving record profits in 2025. Sales of Huatongning exceeded 4 million boxes for the full year.

HUA MEDICINE-B (02552) surged more than 12%, as of the time of publication, up 12.22% to 3.49 Hong Kong dollars, with a turnover of 1442.51 million Hong Kong dollars. In terms of news, HuaLing Medicine announced its performance for the year 2025. During the reporting period, the company's core product, the world's first diabetes new drug, the glucose kinase activator (GKA) Huatangning (Doolglitate tablets), commercialization process accelerated comprehensively, the research and development pipeline continued to enrich, financial performance achieved a historic breakthrough, and successfully entered a new phase of profitability. During the reporting period, product sales reached 4.011 million boxes, a year-on-year increase of 91%; net sales reached 4.929 billion yuan, a year-on-year increase of 93%. The company achieved a record profit in 2025, with a pre-tax profit of 11.064 billion yuan; the cash balance remained stable at the end of the year at 10.923 billion yuan, laying a solid foundation for continued operational development; the gross profit margin increased to 56.9%, with sales expenses accounting for 33.6% of total expenditure, significantly strengthening profitability.